
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight is a commercial-stage medical technology company with a unique and innovative intraocular lens technology that allows for customized vision correction after cataract surgery. The recent collaboration with ALC has the potential to generate significant revenue through upfront and milestone payments, as well as royalties on future product sales. Despite current disappointing underlying trends, RxSight is well-positioned for growth in the second half of 2026, driven by increasing utilization and the potential for improved margins. However, the company's success will depend on its ability to effectively commercialize its products and remain competitive in the IOL market.
Bears say
RxSight is a medical technology company with an adjustable intraocular lens (IOL) product that targets patients undergoing cataract surgery. While the company's recent financials show strong gross margin and revenue beat, the high operating expenses and potential risks such as limited adoption and increased competition in the market makes it difficult to see sustained growth and profitability in the long term.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares